Recruiting
Early Phase 1

Capsaicin

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06744816

Conditions

Peripheral Neuropathy Due to Chemotherapy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Qutenza Patch

Study Details

Brief summary:

To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.

Conditions

Peripheral Neuropathy Due to Chemotherapy

Study ID

NCT06744816

Start date

Dec 11, 2025

Status verified date

Jun, 2026

Completion date

Nov 30, 2027

Anticipated

Primary completion date

Nov 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants diagnosed with pain of the lower extremity from chronic (>90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at MD Anderson Cancer Center
  • Participants reporting baseline pain ≥ 4 (0-10 scale, NRS)
  • Participants age 18+
  • Participants who have completed chemotherapy within the last year at the time of enrollment.

Exclusion Criteria:

  • Participants with cognitive dysfunction
  • Participants with recent history (<6 months) of drug or alcohol abuse
  • Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection
  • Participants with allergies to capsaicin or adhesives
  • Pregnant participants

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Treatment with Qutenza Patch (Topical Capsaicin)

Up to 4 topical capsaicin patches will be applied on your feet for 30 minutes.

Interventions

Qutenza Patch

Given topical

Primary outcome measure

  • Safety and adverse events (AE)s [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts and Locations

Central contacts

Saba Javed, MD

713-792-9530sjaved@mdanderson.org

Locations

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Saba Javed, MD

713-792-9530sjaved@mdanderson.org

Principal Investigator:

Saba Javed, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Jun 26, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-06-26.